American Association for Cancer Research

August 1 Clinical Cancer Research Highlights

PDF Version for Printing pdf4.gif

Selected Articles from the August 1, 2007 Issue

The articles referenced in this Highlights section will be available online in HTML and PDF formats to all interested users at no charge until the next issue of Clinical Cancer Research is published. Click on the article title to view the complete article.

View the Table of Contents for the August 1 issue of Clinical Cancer Research.

Lightscattering Identifies Pancreatic Cancer

Liu et al.

Page 4392

Pancreatic cancer carries a five-year survival rate below 5%. Liu and colleagues developed a novel approach to predict pancreatic cancer through the assessment of the periampullary duodenal mucosa without interrogation of the pancreas. The approach is based on a lightscattering technology that provides assessment of changes in nano/microarchitecture of histologically normal-appearing duodenal mucosa. This technique identified pancreatic cancer patients with 95% sensitivity and 91% specificity. This methodology may provide a highly accurate, minimally invasive means of detecting pancreatic cancer. 
 

Emmprin and Survivin Predict Poor Outcome in Bladder Cancer

Als et al.

Page 4407

Chemotherapy is the standard of care for patients with locally advanced and metastatic bladder cancer, and the response rate is approximately 50%. Als and colleagues used microarray expression profiling to identify genes that correlated significantly with survival time. They identified emmprin and survivin expression, along with immunohistochemistry analyses, as independent prognostic markers for poor outcome in patients with bladder cancer.

Flavopiridol Shows Anti-AML Activity 

Karp et al.

Page 4467

Flavopiridol has anti- acute myelogenous leukemia (AML) activity directly and in combination with ara-C and mitoxantrone. Karp and colleagues conducted a Phase II trial that showed this timed sequential regimen induced durable complete remissions (CRs) in a significant proportion of adults with newly diagnosed secondary AML (including complex cytogenetics) and adults with AML in first relapse after short first CR with a low toxicity profile. Further testing in patients with newly diagnosed, poor-risk AML is warranted. This regimen also serves as a template for testing the new “hybrid” bolus-infusion schedule of flavopiridol administration in combination with ara-C and mitoxantrone.

TroVax is a cancer vaccine in which modified vaccinia Ankara (MVA) is used to deliver the tumor associated antigen 5T4. 5T4 is expressed on the majority of solid tumors but is rarely found on normal tissues. Harrop and colleagues tested TroVax in stage IV colorectal cancer patients receiving a standard of care chemotherapy regimen, and demonstrated that TroVax is safe and induces potent cellular and/or humoral immune responses specific for 5T4 in the majority of patients. Immune responses were detected during the period that patients received chemotherapy. Furthermore, a significant correlation between the 5T4-specific immune responses and clinical benefit was identified. 

Highlights

Highlights: CCR

Highlights: Cancer Research

Highlights: CEBP

Highlights: MCT

AACR Journals

Cancer Research Home

Clinical Cancer Research Home

CEBP

Molecular Cancer Research Home

Molecular Cancer Therapeutics Home

Cancer Reviews Online Home

©2001-2011 American Association for Cancer Research | 615 Chestnut St. 17th Floor, Philadelphia, PA 19106
Contact Us | Sitemap | Privacy Policy | AACR Foundation | AACR Jobs | CancerCareers.org